BioMarin drops BMN401; CSL & Arcturus end mRNA pact with $12M payment; Bavarian Nordic's Imvanex approved for children aged 2-11 in EU.
BioMarin drops rare disease asset after mixed Phase 3: BioMarin decided to discontinue development of BMN401, an enzyme replacement therapy for …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring…
BioMarin Pharmaceutical’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results…
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in…
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid…
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly…
Takeda, Regeneron, Sanofi and BMS trim pipelines in Q2 updates; BMS drops Ph3 prostate cancer degrader BMS-986365, Takeda cuts…
